We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead subsidiary Kite has acquired an exclusive global license for Refuge Biotechnologies’ second-generation CAR-T gene editing platform to develop blood cancer treatments. Read More
Not enough elderly patients are included in drug trials targeting some of their most common illnesses, a new study by FDA researchers concludes. Read More
Milestone Pharmaceuticals’ investigational nasal spray etripamil claimed a phase 3 win, with topline data indicating that abnormal heart rhythms normalized in 64 percent of patients with paroxysmal supraventricular tachycardia (PSVT) compared to 31 percent who used a placebo spray. Read More
GSK has unveiled impressive numbers for its respiratory syncytial virus (RSV) vaccine, touting an overall efficacy rate of more than 94 percent against severe disease in people age 60 years and older. Read More
AstraZeneca is teaming up with DNA sequencing giant Illumina to seek out potential new drug targets using Illumina’s genomic analysis artificial intelligence (AI) technology. Read More
Boston, Mass-based Albireo Pharma said it has hit a phase 3 bull’s eye with Bylvay, an ileal bile acid transport inhibitor under investigation for the treatment of a rare pediatric liver disease called Alagille syndrome. Read More
Sotatercept, Merck’s investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, has scored a phase 3 win, improving physical function and cardiopulmonary outcomes in people with pulmonary arterial hypertension (PAH). Read More